Ausgabe 1/2016
Inhalt (20 Artikel)
Effect of polyphenols on glucose and lactate transport by breast cancer cells
F. Martel, M. Guedes, E. Keating
Potential of breastmilk analysis to inform early events in breast carcinogenesis: rationale and considerations
Jeanne Murphy, Mark E. Sherman, Eva P. Browne, Ana I. Caballero, Elizabeth C. Punska, Ruth M. Pfeiffer, Hannah P. Yang, Maxwell Lee, Howard Yang, Gretchen L. Gierach, Kathleen F. Arcaro
The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer
Cameron P. Capper, José M. Larios, Matthew J. Sikora, Michael D. Johnson, James M. Rae
Apparent diffusion coefficient of breast cancer and normal fibroglandular tissue in diffusion-weighted imaging: the effects of menstrual cycle and menopausal status
Jin You Kim, Hie Bum Suh, Hyun Jung Kang, Jong Ki Shin, Ki Seok Choo, Kyung Jin Nam, Seok Won Lee, Young Lae Jung, Young Tae Bae
Withaferin A inhibits in vivo growth of breast cancer cells accelerated by Notch2 knockdown
Su-Hyeong Kim, Eun-Ryeong Hahm, Julie A. Arlotti, Suman K. Samanta, Michelle B. Moura, Stephen H. Thorne, Yongli Shuai, Carolyn J. Anderson, Alexander G. White, Anna Lokshin, Joomin Lee, Shivendra V. Singh
Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer
Yukiko Tabuchi, Masafumi Shimoda, Naofumi Kagara, Yasuto Naoi, Tomonori Tanei, Atsushi Shimomura, Kenzo Shimazu, Seung Jin Kim, Shinzaburo Noguchi
Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer
Andrew R. Green, D. Soria, D. G. Powe, C. C. Nolan, M. Aleskandarany, M. A. Szász, A. M. Tőkés, G. R. Ball, J. M. Garibaldi, E. A. Rakha, J. Kulka, I. O. Ellis
Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer
A. Thakkar, B. Wang, M. Picon-Ruiz, P. Buchwald, Tan A. Ince
Prognostic impact of breast cancer subtypes in elderly patients
E. S. Bergen, C. Tichy, A. S. Berghoff, M. Rudas, P. Dubsky, Z. Bago-Horvath, R. M. Mader, R. Exner, M. Gnant, C. C. Zielinski, G. G. Steger, M. Preusser, R. Bartsch
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14
Judith-Anne W. Chapman, Dennis C. Sgroi, Paul E. Goss, Elizabeth Zarella, Shemeica Binns, Yi Zhang, Catherine A. Schnabel, Mark G. Erlander, Kathleen I. Pritchard, Lei Han, Tanja Badovinac-Crnjevic, Lois E. Shepherd, Michael N. Pollak
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
Daniel Rayson, Sasha Lupichuk, Kylea Potvin, Susan Dent, Tamara Shenkier, Sukhbinder Dhesy-Thind, Susan L. Ellard, Catherine Prady, Muhammad Salim, Patricia Farmer, Ghasson Allo, Ming-Sound Tsao, Alison Allan, Olga Ludkovski, Maria Bonomi, Dongsheng Tu, Linda Hagerman, Rachel Goodwin, Elizabeth Eisenhauer, Penelope Bradbury
Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes
Kristen S. Purrington, Daniel W. Visscher, Chen Wang, Drakoulis Yannoukakos, Ute Hamann, Heli Nevanlinna, Angela Cox, Graham G. Giles, Jeanette E. Eckel-Passow, Sotiris Lakis, Vassiliki Kotoula, George Fountzilas, Maria Kabisch, Thomas Rüdiger, Päivi Heikkilä, Carl Blomqvist, Simon S. Cross, Melissa C. Southey, Janet E. Olson, Judy Gilbert, Sandra Deming-Halverson, Veli-Matti Kosma, Christine Clarke, Rodney Scott, J. Louise Jones, Wei Zheng, Arto Mannermaa, Diana M. Eccles, Celine M. Vachon, Fergus J. Couch
Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL)
Dawn L. Hershman, Lawrence H. Kushi, Grace Clarke Hillyer, Ellie Coromilas, Donna Buono, Lois Lamerato, Dana H. Bovbjerg, Jeanne S. Mandelblatt, Wei-Yann Tsai, Xiaobo Zhong, Judith S. Jacobson, Jason D. Wright, Alfred I. Neugut
Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
Christopher M. Gallagher, Kenneth More, Tripthi Kamath, Anthony Masaquel, Annie Guerin, Raluca Ionescu-Ittu, Marjolaine Gauthier-Loiselle, Roy Nitulescu, Nicholas Sicignano, Elizabeth Butts, Eric Q. Wu, Brian Barnett
Neo-adjuvant doxorubicin and cyclophosphamide followed by paclitaxel in triple-negative breast cancer among BRCA1 mutation carriers and non-carriers
Shani Paluch-Shimon, Eitan Friedman, Raanan Berger, Moshe Papa, Maya Dadiani, Neil Friedman, Moshe Shabtai, Dov Zippel, Mordechai Gutman, Talia Golan, Ady Yosepovich, Raphael Catane, Tami Modiano, Bella Kaufman
Ethnic differences in the relationships between diabetes, early age adiposity and mortality among breast cancer survivors: the Breast Cancer Health Disparities Study
Avonne E. Connor, Kala Visvanathan, Kathy B. Baumgartner, Richard N. Baumgartner, Stephanie D. Boone, Lisa M. Hines, Roger K. Wolff, Esther M. John, Martha L. Slattery
Association of adiposity, dysmetabolisms, and inflammation with aggressive breast cancer subtypes: a cross-sectional study
Roberto Agresti, Elisabetta Meneghini, Paolo Baili, Pamela Minicozzi, Alberto Turco, Ilaria Cavallo, Francesco Funaro, Hade Amash, Franco Berrino, Elda Tagliabue, Milena Sant
Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis
P. Lavaud, B. Rousseau, Z. Ajgal, J. Arrondeau, O. Huillard, J. Alexandre, A. Hulin, F. Goldwasser
Racial differences in receipt of adjuvant hormonal therapy among Medicaid enrollees in South Carolina diagnosed with breast cancer
Tisha M. Felder, D. Phuong Do, Z. Kevin Lu, Lincy S. Lal, Sue P. Heiney, Charles L. Bennett